Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance.

NPJ Precis Oncol · 2023 · PMC10182067 · PMID 37173424

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Interestingly, only addition of low-dose everolimus (mTORC1 inhibitor) to anti-PD-1 led to better bladder or cervical cancer control 124 , 125 , while addition of high-dose everolimus to anti-PD-1 showed a trend towards worse tumour control 124 .

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.